Chip Davis: “The Biosimilars Wave is Coming. Are Pharmacists Prepared?”

Thursday May 9, 2019

In a recent for Drug Store News, Chip Davis, President and CEO for the Association of Accessible Medicines, discusses the important role pharmacists will play in the education and adoption of biosimilars.

“As trusted partners for patients, pharmacists play a critical role. They are and will continue to be a critical voice in educating patients on biosimilar medicines” says Davis. Pharmacists are in a unique position to discuss biosimilar availability and options with patients and doctors alike.

Adoption of biosimilars is something everyone should be concerned about. Estimates from various economic impact studies pin the projected savings from $44 billion on the low end to as high as $250 billion over 10 years and $378 billion over 20 years. While statistical assumptions for each analysis vary, experts agree on the transformative potential and significant savings from biosimilars.

To learn more about biosimilars and to stay up to date on the latest biosimilars news, visit, or follow us on Twitter, Facebook and LinkedIn.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.